3 factors predict 10-year survival in differentiated thyroid cancer

  • Kelly A & al.
  • PLoS ONE
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • American Thyroid Association (ATA) classification, age, and preablation stimulated thyroglobulin (sTG) levels are associated with 10-year survival in patients with differentiated thyroid cancer (DTC), according to a retrospective study.

Why this matters

  • Relatively few studies have analyzed OS rates and associated prognostic factors for patients with DTC.

Key results

  • Multivariate factors for reduced 10-year OS:
    • Initial ATA high (OR, 21.9; 95% CI, 8.5-56.3) or intermediate (OR, 4.7; 95% CI, 2.9-7.5) recurrence risk classification.
    • Age 45-55 years (OR, 4.9; 95% CI, 2.7-8.7) or >55 years (OR, 23.8; 95% CI, 7.5-75.3).
    • Preablation sTG ≥30 μg/L (OR, 8.4; 95% CI, 4.6-15.3).
  • Patients were stratified into 3 groups on the basis of these factors and associated survival:
    • Excellent: 10-year OS of 99% in patients
    • Moderate: 10-year OS of 94.5% in patients
    • Low: 10-year OS of 49% in patients ≥55 years with preablation sTG ≥30 μg/L.

Study design

  • 1093 patients with DTC who received radioactive iodine ablation after thyroidectomy were included.
  • Funding: None.

Limitations

  • Retrospective study design.